Title: Effects and Safety of Cyclophosphamide Combined With Glutathione in Treatment of Interstitial Lung Disease Associated With Primary Sjogren Syndrome
Abstract: Objective To evaluate the efficacy and safety of Cyclophosphamide(CTX) combined with glutathione(GSH) in treatment of interstitial lung disease associated with primary Sjogren syndrome(ILD-pSS). Methods 86 cases of ILD-pSS were randomly divided into treatment and control groups. All patients were treated with hydroxychloroquine,glucocorticoids and cyclophosphamide pulse; While patients in treatment group were treated with reduced glutathione 2.4 g/d before and after the application of cyclophosphamide pulse for 7 days. Lung HRCT, pulmonary function, blood erythrocyte sedimentation rate, liver function, immunoglobulin and the clinical symptoms were observed before and after treatment for 6 months. Results Compared with untreated patients, pulmonary HRCT, pulmonary function, ESR, CRP, immunoglobulin were markedly improved after treatment for 6 months in two groups(P0.01).Clinical parameters were improved better in treatment group than in the control group (P0.05).Compared with the control group,the rates of adverse events were significantly decreased in treatment group(P0.001).Conclusion 1. cyclophosphamide pulse was effective strategy for pSS-ILD. 2. Compared with cyclophosphamide pulse treament alone, the effect and security were significantly improved by the treatment combined cyclophosphamide pulse with glutathione for patients with pSS-ILD.
Publication Year: 2011
Publication Date: 2011-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot